Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)

COMMENTED

Lung Cancer

Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Curr Oncol

Cheung WY, Lee A, Bote de Cabo H, Burdenski K, Christopoulos P, Pinto-Correia B, Deshayes S, Girard N, Hindocha P, Madden Á, Mella M, Moreira J, Rizzi S, Abreu DR, Soares M, Thomas J, Han M, Calvet CY, Emanuel G, Glassberg MB, Jacobs H, Rault C, Yuan Y, Chouaid C

doi: 10.3390/curroncol33030152

Lung Cancer

Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort

Clin Lung Cancer

Williams C, Rogers J, Arasaratnam D, Pham T, Nguyen A, Rashed L, Tadesse F, Truong A, Zhang H, Selbie L, Geng J, Tan L, Harden S, Solomon BJ, Alexander M

doi: 10.1016/j.cllc.2026.03.007

RECOMMENDED

Lung Cancer

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Lee J, Kim M, Han HJ, Kim S, Suh HS

doi: 10.1016/j.lungcan.2025.108682

Lung Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

Lung Cancer

Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)

Lung Cancer

Ciammella P, Iori F, Borghetti P, Galaverni M, Alì E, Tiseo M, Pagano M, Sepulcri M, Scotti V, GiajLevra N, Marcenaro M, Simoni N, Nardone V, Botti A, Cozzi S, Bruni A

doi: 10.1016/j.lungcan.2025.108718

Lung Cancer

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Oncol Ther

Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N

doi: 10.1007/s40487-026-00437-8

RECOMMENDED

Lung Cancer

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

Adv Ther

Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M

doi: 10.1007/s12325-025-03465-4

Lung Cancer

KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort

J Clin Med

Geçgel A, Şahin Çelik B, Peker P, Gökdere ZS, Koca D, Karaca B, Nart D, Göker E

doi: 10.3390/jcm14196826

Lung Cancer

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)

Lung Cancer

Hayasaka K, Shimokawa M, Haratake N, Notsuda H, Katsumata S, Hamada A, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita I, Takamori S, Muto S, Takanashi Y, Mizuno K, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Shiono S, Soh J, Ohde Y, Okada Y

doi: 10.1016/j.lungcan.2026.108908

Related content

Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)